Iressa Relabeling Reflects Competing Risk/Benefit Interests – CDER’s Galson
Executive Summary
FDA's decision to limit the use of Iressa (gefitinib) is indicative of the agency's attempt to incorporate competing interests in a risk/benefit analysis, Center for Drug Evaluation & Research Acting Director Steven Galson said June 21
You may also be interested in...
Iressa Coverage Under Part D Should Be Consistent With On-Label Use – WLF
AstraZeneca's oncology drug Iressa should be reimbursed under Medicare Part D for lung cancer patients who are already benefiting from it, the Washington Legal Foundation urges in Aug. 19 comments to the Centers for Medicare & Medicaid Services
Iressa Coverage Under Part D Should Be Consistent With On-Label Use – WLF
AstraZeneca's oncology drug Iressa should be reimbursed under Medicare Part D for lung cancer patients who are already benefiting from it, the Washington Legal Foundation urges in Aug. 19 comments to the Centers for Medicare & Medicaid Services
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials